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CHK1 expression in Gastric Cancer 
is modulated by p53 and RB1/E2F1: 
implications in chemo/radiotherapy 
response
J. Bargiela-Iparraguirre1,*, L. Prado-Marchal1,*, M. Fernandez-Fuente2, A. Gutierrez-
González1, J. Moreno-Rubio3,4, M. Muñoz-Fernandez5, M. Sereno3, R. Sanchez-Prieto6,7, 
R. Perona1,8,9 & I. Sanchez-Perez1,7,8,9
Radiation has a limited but relevant role in the adjuvant therapy of gastric cancer (GC) patients. Since 
Chk1 plays a critical function in cellular response to genotoxic agents, we aimed to analyze the role 
of Chk1 in GC as a biomarker for radiotherapy resistance. We analyzed Chk1 expression in AGS and 
MKN45 human GC cell lines by RT-QPCR and WB and in a small cohort of human patient’s samples. 
We demonstrated that Chk1 overexpression specifically increases resistance to radiation in GC cells. 
Accordingly, abrogation of Chk1 activity with UCN-01 and its expression with shChk1 increased 
sensitivity to bleomycin and radiation. Furthermore, when we assessed Chk1 expression in human 
samples, we found a correlation between nuclear Chk1 accumulation and a decrease in progression 
free survival. Moreover, using a luciferase assay we found that Chk1’s expression is controlled by 
p53 and RB/E2F1 at the transcriptional level. Additionally, we present preliminary data suggesting 
a posttranscriptional regulation mechanism, involving miR-195 and miR-503, which are inversely 
correlated with expression of Chk1 in radioresistant cells. In conclusion, Chk1/microRNA axis is involved 
in resistance to radiation in GC, and suggests Chk1 as a potential tool for optimal stratification of 
patients susceptible to receive adjuvant radiotherapy after surgery.
Gastric cancer (GC) is the fourth most common human malignant disease worldwide due to its frequency and 
high rate of mortality1,2. Classical adjuvant treatment in GC is based on MacDonald´s protocol including a com-
bination of 5-Fluoruracil (5-FU) and radiation (IR) in stage IB-IVA patients. This regimen demonstrated an 
increase of progression free survival (PFS) and overall survival (OS)3,4. However, this combination is usually asso-
ciated with increased, severe toxicity3. Thus, identification of those patients more prone to benefit from adjuvant 
radiation and 5-FU after curative surgery for GC to counteract such toxicity is an unmet need5,6.
Radiation and chemotherapy routinely used to treat cancer do cause a variety of DNA lesions, which in 
turn activate DNA damage response (DDR)7. Checkpoint Kinase 1 (Chk1), a key effector in DDR, is a multi-
functional Ser/Thr kinase protein highly conserved through evolution8 and represents a crucial component in 
all cell cycle checkpoints. Chk1 activation must be finely regulated to ensure its adequate activity. The major 
known to date mechanism controlling Chk1 regulation is the phosphorylation of specific residues Ser317 and 
Ser345 (both in the C-terminal domain), which leads to catalytic activation. These reactions are catalyzed by 
ATR and ATM kinases7–9. Deregulation of Chk1 expression has been previously described in cancer, i.e. Chk1 is 
overexpressed7,10–12 and has been correlated with radiotherapy resistance in some cancer types such as ovarian 
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cancer13, nasopharyngeal carcinoma14 and lung cancer15. Accordingly, inhibition of Chk1 increases sensitivity 
to chemo-radiotherapy in multiple tumor models16,17. Given this apparent relationship between Chk1 expres-
sion and resistance to certain therapies, some groups have made an effort to evaluate Chk1 as a novel target to 
improve cancer therapy18 in patients that have been previously exposed to ionizing agents. Besides the well known 
mechanisms regulating both activation and expression of Chk1 that have already been described10,19–23, Chk1 is 
also regulated at the post-transcriptional level by microRNAs (miRNAs)24,25 which are key regulators of tumor 
growth and response to chemotherapy26–28. In fact, some studies have already begun to identify miRNAs involved 
in sensitizing or causing resistance to chemotherapy, thus providing potential new targets and mechanisms as 
optimized treatment options29–31.
Previous studies from our laboratory suggested that Chk1 levels could be used as a predictive biomarker 
of therapeutic response in colon cancer32. Furthermore, we demostratred that E1A upregulates Chk1 and this 
correlates with glioblastoma radiosensitivity33. Here, we prove that Chk1 is overexpressed in a disseminated GC 
cell line, MKN45. We have shown that the inhibition of Chk1 results in increased IR sensitivity. Accordingly, we 
observed nuclear accumulation of Chk1, which correlates with a lower PFS period, in a cohort of patients treated 
with IR. The results we present here, suggest that Chk1 protein levels are controlled at the transcriptional level 
mainly through RB1/E2F1 and our preliminary data suggest that at the posttranscriptional level they are likely 
regulated by miRNA-195 and -503. We conclude that Chk1 is responsible for radiation resistance in GC, and 
suggest Chk1 as a potential biomarker for the optimal stratification of patients susceptible to receive adjuvant 
radiotherapy after surgery.
Results
Increased Chk1 expression correlates with resistance to genotoxic agents in GC cells. We stud-
ied the sensitivity of the two most common human gastric adenocarcinoma cell lines (AGS and MKN45) to anti-
tumoral agents: cisplatin (CDDP), 5-FU, the radiomimetic agent Bleomycin (BLM) and IR. Dose response curves 
using this set of drugs showed that after 48 hours of treatment, MKN45 cells are more resistant than AGS cells to 
both BLM or IR treatment (Fig. 1A), with this increased resistance more evident after BLM treatment. To cor-
roborate this result we conducted a clonogenic assay, and observed that the percentage of colony formation was 
higher on MKN45 cells than on AGS after 4 Gy irradiation (i.e: 89,6% vs 48.7% respectively) (Fig. 1B). Similarly, 
when treated with BLM, AGS cells were unable to form colonies at all (Supplementary Fig. 1A); Furthermore, 
we also observed morphological changes characteristic of cell death in irradiated AGS cells, which were com-
pletely absent in MKN45 cells (Fig. 1B). To support this finding we irradiated cells with 4 and 8 Gy for 24 hours. 
We observed cleavage of PARP, and also a decrease in the full-length form of this protein in AGS cells in a dose 
dependent manner. However, in MKN45 we only observed basal levels of PARP with no change in proteolysis. 
Furthermore, the universal marker of apoptosis, activation of Caspase 3, is also observed in the AGS cell line, with 
particularly strong activity after 8Gy treatment (Fig. 1B).
Given that Chk1 is one of the main effector proteins on the response to IR exposure, we examined the expres-
sion levels of Chk1 in MKN45 and AGS cells by RT-QPCR and western blot (WB). Our results showed an increase 
on Chk1 mRNA and protein levels in both MKN45 and AGS cells when compared to normal tissue. Two differ-
ent isoforms of Chk1 have been described34 and our WB analysis indicated that the more abundantly expressed 
isoform in MKN45 is the classic Chk1 with higher molecular weight (Fig. 1C). We confirmed this result by 
analyzing the expression of this gene, using public data available on Oncomine database (http//:oncomine.org) 
(Supplementary Fig. 1B). Our semi-quantitative PCR analysis confirmed the expression of both full-length and 
short forms of Chk1 in these two cell lines (Supplementary Fig. 1C). Altogether, these results suggest that elevated 
levels of Chk1 in GC cells correlate with a lack of apoptotic response to IR or BLM treatment.
Chk1 inhibition reduces radioresistance in GC cell lines. To confirm the effect of Chk1 on survival to 
double strand breaks (DBS) induced by BLM or IR treatment in GC cells, we inhibited Chk1 activity by using the 
chemical inhibitor UCN-01 prior to treatment. Inhibition of Chk1 with 100 nM UCN-01 (no toxicity observed) 
increased mortality rate in combination with BLM treatment (0–100 μ g/ml). Addition of UNC-01, significantly 
decreased IC50 in both cell lines: from 2.45 to less than 1 μ g/ml in AGS and from over 100 to 11 μ g/ml in MKN45 
cells (Fig. 2A-Left panel). On the other hand, treatment with BLM using 3 μ g/ml for AGS cells and 10 μ g/ml for 
MKN45 followed by UCN-01 (0–600 nM) also sensitized both cell lines (Fig. 2A- Right panels); however the dose 
of UCN-01 required to increase sensitivity to BLM in MKN45 cells was highly toxic (> 400 nM). These results 
suggest a potential synergistic or additive effect upon the combination treatment of BLM with UCN-01. We 
therefore used the Combination Index (CI) equation method developed by Chou-Talalay35 using the CalcuSyn 
program to study combinational synergistic effects. Our studies revealed that in AGS cells both drugs exhibit 
a synergistic effect (CI < 1) at all the UCN-01 doses tested in combination with BLM. By contrast, when using 
MKN45 cells we only observed that synergistic effect (CI < 1) at very high toxic doses of UCN-01. Furthermore, 
in this cell line our drugs exerted an antagonistic effect (CI > 1) at lower doses. To further assess the contribution 
of Chk1 in the response to therapy, we downregulated Chk1 by pharmacological agents (UCN-01) or silenced 
it using shRNA lentiviral particles. Next, we analyzed the cell cycle profile after challenge with BLM in cells that 
had been pre-treated with UCN-01 or after interference on Chk1’s expression. We observed a drastic abrogation 
of the G2/M checkpoint after both treatments, which was even more dramatic when Chk1 is interfered with by 
our lentivirus (Fig. 2B). Furthermore, we found that the percentage of apoptotic cells was increased in both cell 
lines after the combination treatment (UCN-01+ IR) (Fig. 2C- Graph). The analysis of the G2/M and S indexes 
indicated that UCN-01 abolishes the G2/M and Intraphase S checkpoint in GC cells further supporting the con-
tribution of Chk1 to radiation resistance (Fig. 2C- Table). To confirm that UCN-01 inhibits Chk1, we monitored 
Chk1 autophosphorylation on Ser296 as previously described36 (Supplementary Fig. 2A). As a control confirming 
Chk1’s silencing we observed that after 72 hours, AGS cells showed almost complete abolishment of Chk1 mRNA 
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expression and around a 60% reduction for MKN45 cells (Supplementary Fig. 2B). Taken together, the data pre-
sented here suggest that Chk1 depletion results in enhanced sensitivity, lower survival rates following exposure to 
radiation, and altered G2/and intra-S checkpoint responses to DSBs induced damage.
Transcriptional regulation of Chk1 in GC cells. To study whether high levels of Chk1 occur due to alter-
ations at the transcriptional level, we cloned a fragment of Chk1 corresponding to the 5′ Flanking region of the 
Figure 1. CHK1 mRNA levels are high in GC cells resistant to radiation (IR) and bleomycin (BLM). 
(A) Survival of AGS and MKN45 cells after CDDP, 5-FU, BLM or IR treatment. AGS (○ ) and MKN45 (● ) 
cells were treated with increasing amounts of CDDP (0–10 μ g/ml), 5-FU (0–1000 μ M), BLM (0–100 μ g/ml) 
or IR (0–8 Gy). 48 h after treatment, the percentage of viable cells was quantified by the MTS method. Data 
represent the mean values obtained in two experiments performed in quadruplicate. (B) Clonogenic assay 
in AGS and MKN45 cells 13 days after irradiation with different doses of Gy (0–8); the graph shows the 
percentage of CFU (colony forming units). Representative images of AGS and MKN45 cells, 13 days after 
irradiation (4 Gy) are shown. The arrows point to abnormal morphology in AGS cells. Cleavage of PARP-1 
was detected by western blot (WB) in cells harvested 24 h after 4 and 8 Gy IR. Activation of Caspase 3 was 
detected in the same extracts as above, running under the same experimental conditions. (Full length 
blot is included in supplementary information). α -Tubulin was used as a loading control. (C) RT-QPCR 
analysis of CHK1 expression in asynchronous cultures of AGS and MKN45 cells. The graph shows the 
relative levels of CHK1’s mRNA compared to normal tissue (NT), and using GAPDH as endogenous 
control. WB for both Chk1 isoforms (Chk1 and Chk1-S) in whole cell extracts from asynchronous cultures 
of AGS and MKN cells. α -Tubulin was used as a loading control.
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Figure 2. Chk1 inhibition sensitizes GC cells to BLM or IR. (A) Survival rates in AGS and MKN45 cell lines, 
after treatment with BLM (0–100 μ g/ml) and in the presence (● ) or absence (○ ) of 100 nM UCN-01. Histogram: 
Viability percentage for AGS and MKN45 cells treated with increasing doses of UCN-01 (0–600 nM) in the 
presence or absence of BLM (3 μ g/ml and 10 μ g/ml for AGS and MKN45 cells respectively). (B) Cell cycle profile 
after inhibition of Chk1 by treatment with the inhibitor UCN-01 (100 nM for AGS or 300 nM for MKN45 cells) or 
after silencing Chk1’s expression by transient transduction with a lentivirus carrying shRNA- Chk1 for 72 hours. 
One hour after, cells were treated with vehicle or with BLM (3 ug/ml) for 24 hours. Plots are representative of an 
experiment performed twice in duplicate. AP: Apoptotic Cells, G2/M: cells in G2 or Mitosis. (C) Percentage of 
apoptotic cells in both cell lines after irradiation, UCN-01 treatment and UCN-01 plus IR. Table containing G2/M 
and S accumulation index in both cell lines after IR and with or without UCN-01 treatment.
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gene, (− 1823 − 284, as predicted by the Transfac tool) which contains the transcription factor (TF) and binds to 
CHK1’s promoter (Supplementary Fig. 3A), in the pGL3-Basic enhanced luciferase plasmid. We detected lucif-
erase activity after transient transfection in AGS and MKN45 cells; this occurred in both cell lines in a DNA- dose 
dependent manner, confirming that the generated construct is functional (Supplementary Fig. 3B). First, we 
focused on p53 and E2F1. E2F1 expression in AGS cells reached a 6-fold increase over pGL3-F0; however, only 
a 2-fold increase was observed in MKN45 cells (Fig. 3A). Next, we analyzed if both E2F1 and p53 cooperate in 
modulating Chk1 expression in GC cells. We verified that both cells lines are p53 wild type37,38 and also performed 
a WB in order to evaluate the status of p53 in our specific experimental conditions, and our results indicated that 
p53 activation is equivalent in both cell lines. We found a transient activation of p53 4 h after IR (8 Gy) which 
returns to basal levels 24 hours after. We did not observe differences in p53 basal levels either (Supplementary 
Fig. 3C). To analyze the contribution of E2F1 and p53 in Chk1 expression, we performed an experiment in which 
cells were co-transfected with E2F1 (250 ng) and pGL3-F0 (200 ng) expression plasmids and increasing doses of 
the p53 (0–1 μ g) expression vector. Our results showed that p53 was able to inhibit the transcriptional activity 
induced by E2F1 expression in GC cells, in a dose-dependent manner (Fig. 3C). We also tested the Dominant 
Negative (DN) form of p53 that was indeed able to revert the p53-dependent down-regulation of Chk1 when 
co-transfected with E2F1 and pGL3-F0, which further supported the involvement of p53 in Chk1 promoter reg-
ulation (Fig. 3D). To confirm that p53 regulates Chk1 promoter in vivo, cells were co-transfected with a plasmid 
Figure 3. Chk1’s promoter activity is regulated by E2F1 and p53 in GC cell lines. (A) Cells were transfected 
with increasing doses (0–1 μ g) of an E2F1 expression vector (pCMV-E2F1), the corresponding empty control 
expression vector, and 200 ng of pGL3-F0. The graph shows activity levels, relative to that of PGL3-F0. (B) AGS 
and MKN45 cells were transfected with 200 ng of PGL3-F0, 500ng pCMV-E2F1 and increasing doses of p53’s 
expression vector (0–1 μ g). Results are presented as activity level, relative to that of the empty pGL3-Luc reporter 
in the presence of E2F1. (C) Left graph: MKN45 cells were transfected with 200 ng pGL3-F0 and expression 
vectors for E2F1 (250 ng), E2F1 plus p53 or E2F1 plus DNp53. Right graph: Both MKN45 and AGS cells were 
transfected with 200 ng pGL3-F0 and expression vectors for E2F1 (250 ng) or HEY1 (200 ng). All data are 
presented as the average of at least three independent experiments assayed in triplicate ± SEM. p < 0,05 versus 
empty vector control (Student’s t test).
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encoding the Hey1 protein, which is an activator of p5339 and pGL3-F0. Hey1 completely repressed the activity 
of Chk1 promoter after E2F1 expression in AGS cells and strongly inhibited it (50%) in MKN45 cells (Fig. 3D). 
To verify that these TFs control Chk1’s expression in AGS cells, we quantified Chk1’s mRNA levels under the 
above conditions. Our results suggest that E2F1 increases Chk1 expression and that activation of p53 reduces it 
(Supplementary Figure 3D). These results suggest that transcriptional regulation in these cells could be differ-
entially modulated in GC adenocarcinoma through changes on E2F1 protein levels. The “in silico” analysis of 
the promoter sequence, revealed the presence of different E2F1 binding sites; therefore, we performed different 
deletions of the 5′ UTR (F2) and (F3), taking into account the putative TF binding sites for E2F. F2 and F3 are 
fragments that contain two and one E2F binding sites respectively (Fig. 4A). We found a drastic decrease in the 
transcriptional activation in AGS cells dependent on the number of E2F1 binding sites; however, no significant 
differences were observed in MKN45 cells. This suggests that the two E2F1 binding sites located in the area 
between − 1843 − 1201 pb (lost in F2 and F3) play a pivotal role in the induction of the promoter activity, espe-
cially in the AGS cell line, which suggests that other mechanisms are involved in the regulation of CHK1 mRNA 
levels in MNK45 cells (Fig. 4A).
To further explore the mechanism involved in Chk1 expression by E2F1 and to gain insight into the differ-
ences found in E2F1 regulation between these cell lines, we studied the basal expression of RB1 and E2F1 proteins 
Figure 4. The RB1/E2F1 axis controls activation of Chk1 promoter. (A) Schematic representation of the 
constructs used in the transfection experiments. AGS and MKN45 were transfected with 250 ng of the indicated 
construction, and luciferase activity was measured 24 h later. The histograms show relative activity normalized 
to the empty vector in both AGS and MNK45 cells. (B) Expression of both RB1 and E2F1 was detected by WB 
using specific antibodies in AGS and MKN45 cells. α -Tubulin was used as loading control. The experiments 
were repeated three times with similar results. The graph on the center represents relative expression level 
(log 2-copy number) of RB1 in control (Hs 738St/Int) and tumoral AGS and MKN45 cells obtained from the 
Oncomine database. The graph on the right shows luciferase activity measurements in AGS and MKN45 cells 
after transfection with 250 ng of F0 and 100 ng of PCEFL-E1A. The data are presented as activity relative to the 
values found for the empty vector in transfected cells. The experiment was performed twice in triplicate.
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in each cell line. Our results indicate that levels of both RB1 and E2F1 are higher in MKN45 than in AGS cells 
(Fig. 4B). The expression of the RB gene through the Oncomine database (http//:oncomine.org), confirmed our 
finding of high levels of RB1 mRNA in MKN45 cells (Fig. 4B middle graph). We took advantage of the ability of 
adenovirus E1a protein to bind and block this tumor suppressor gene RB40,41. Transfection of a plasmid encoding 
the E1a protein in both cell lines, resulted in a clear increase on the activity of Chk1 promoter, which was more 
dramatic in MKN45 cells (Fig. 4B- right graph). These results indicate that the lack of transcriptional activation 
of Chk1 promoter in MKN45 cells and to a lower extent in AGS cells, could be due to effects exerted by the RB1 
protein through binding to the TF E2F1.
The above results do not completely justify the high level of CHK1 messenger in MKN45 cells. Therefore, we 
investigated if the increase on CHK1 mRNA level in MKN45 cells is a result of post-transcriptional regulation. 
To investigate this possibility, we treated AGS and MKN45 cells with the transcriptional inhibitor Actinomycin D 
(Act D). CHK1 mRNA level was reduced 9 hours after Act D treatment in AGS cells (0,75-fold). However, in the 
MNK45 cell line, mRNA was accumulated at the same time (2,66-fold) (Supplementary Fig. 4A). These results 
suggest that CHK1 mRNA stability is regulated at post-transcriptional level in MKN45 cells.
Therefore, we decided to investigate the expression of microRNAs in samples from human GC cells in order 
to find miRNA candidates to regulate Chk1 expression. To this end, we analyzed the gene expression dataset 
GSE3007042, and found that the levels of microRNA predicted by the online software TARGETSCAN for CHK1 
were significantly different between cancer and control samples (Supplementary Fig. 4B). From the predicted 
miRNAs that target CHK1, we investigated the potential role of miR-195 and miR-503 in the regulation of the 
stability of CHK1 mRNA. miR-195 belongs to the big miR-15 microRNA family. This family has been recently 
described as radiosensitivity enhancer on breast cancer by targeting CHK143 and miR-503 has been previously 
shown to target CHK144,45. We then used real-time PCR to detect the expression of miR-195/503 in AGS and 
MKN45 cell lines. Our results showed that miR-195 and -503 levels were significantly lower (P ≤ 0.05) in MKN45 
cells than in AGS cells (Supplementary Fig. 4B). Taken together, these data suggest an involvement of miR-195 
and -503 in the upregulation of CHK1 mRNA in MKN45 cells.
Prognostic Relevance of Chk1 Expression in gastric tumors. To assess the clinical significance of 
these findings, we studied the levels of Chk1 protein in a small cohort of patients. The samples were selected from 
patients that had received adjuvant therapy (Radiotherapy plus 5-FU) after surgery. The overall features of all 
23 patients are summarized in Table 1. No significant association between Chk1 levels and age, sex, stage of the 
tumor, Lauren and Her2+ expression or PFS was observed in patients with GC (p > 0,05). However, our analy-
sis detected 6 cases with positive Chk1 nuclear staining versus 14 cases that did not show any staining for Chk1 
(Fig. 5A). Interestingly, we observed that patients with nuclear Chk1 accumulation tended to have shorter PFS 
than those with negative nuclear Chk1 staining (17,67 months vs 25,21 months; p = 0.059). The Kaplan-Meyer 
curve showed early differences in PFS between both populations (Fig. 5B). Altogether these results suggest that 
GC Characteristic
CHK1 Low CHK1 High
n* (%) (%) X2 P
SEX
 Male 19 68,5 31,5 1.709 0.539
 Female 4 100 0
AGE (mean) 63,3 74 0.389
STAGE
 I 3 100 0 2.841 0.417
 II 7 57,1 42,9
 III 6 83,3 16,7
 IV 1 100 0
LAUREN
 Intestinal 8 87,5 12,5 0.410 0.522
 Difusse 8 75 25
HER2/erb-b2
 Positive 2 50 50 0.647 0.421
 Negative 17 70 30
PFS (Months)
 ≤ 18 5 40 60 4.752 0.063
 > 18 11 90 10
Table 1.  The association of Chk1 nuclear expression with the clinicopathological characteristics of 
Gastric Cancer patients. Results from a total of 23 patient samples. Correlation between clinicopathological 
characteristics and Chk1 nuclear expression was assessed by Chi2 or Fisher exact test and t-test to compare the 
mean age between groups. Statistical significance was considered when p < 0.05, using IBM SPSS Statistics 22 
software. *Patients with missing clinicopathological information in their medical records.
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Chk1 can be considered as a putative biomarker for radiotherapy response in GC patients, since Chk1 protein 
level correlates with poor clinical outcome in human GC.
Discussion
Combining chemotherapy with radiation improves outcome in GC, but this strategy comes with the price of an 
increased toxicity rate and furthermore, many of these tumors are resistant to radiation. To overcome this obsta-
cle, it is crucial to identify the key determinants of radioresistance, since this will enable us to develop safer and 
more effective tumor radiosensitizers.
We have previously reported that CDDP-resistance in colorectal cancer cells correlates with high Chk1 lev-
els32. Here, we have demonstrated a relationship between Chk1 expression and IR resistance in GC. Our results 
indicate that in GC cell lines, Chk1 is upregulated and specifically modulates sensitivity to radiation. This upreg-
ulation correlates with poor clinical prognosis in our patient cohort and can be explained by acquired resistance 
to IR. Taking into account that GC is generally diagnosed at advanced stages, it is difficult to recruit a large cohort 
of patients meeting our inclusion criteria (gastrectomy plus adjuvant therapy based on 5-FU plus IR). However, 
it is necessary now to reproduce our results in a larger cohort of patients, to confirm the implication of Chk1 on 
therapy response and also to clarify other clinical and pathological outcomes. Our data indicate that inhibition of 
Chk1 activity due to treatment with UCN-01, increases sensitivity to both BLM and IR. This evidence points to 
Chk1 as a good target in GC treatment. Unfortunately, clinical development of UCN-01 has been halted due to 
unfavorable pharmacology46. However, other inhibitors have been tested such as AZD7762 (a potent and selective 
ATP-competitive Chk1 kinase inhibitor), which has shown strong chemosensitizing activity when used alongside 
DNA-damaging agents. This has been evaluated both in in vitro and in vivo model systems47. Increasing evidence 
indicates that Chk1 inhibitors are able to synergize with antitumoral drugs in an specific molecular context, such 
as tumors with defects in the DNA damage repair pathway, or those overexpressing specific oncogenes48.
According with data from the literature, transcriptional regulation of Chk1 is controlled through p53 and 
E2F149,50. In our experimental model radioresistance of MKN45 cells is not dependent on p53, since in both cell 
lines used in our study, p53 is wild type37. We corroborated that p53 is equally activated and follows the same 
kinetics in both cell lines after IR treatment. Our luciferase assays demonstrated that p53 regulates negatively the 
transcriptional activation of Chk1; moreover, we also confirmed that overexpression of p53 by transfection, leads 
to downregulation of Chk1 mRNA in vitro.
We cloned the Chk1 promoter region which contains different E2F binding sites50. The RB1-E2F1 pathway is 
crucial for the regulation of cell cycle progression and tumorigenesis. RB1 is a tumor suppressor gene frequently 
mutated or deleted in cancer, however in GC it is also amplified in an important percentage of samples51. Our 
results support a definitive role of RB1-E2F1 in the regulation of Chk1 transcription in GC. We suggest that in 
basal conditions E2F1 is sequestered by RB1, which is then unable to induce the expression of Chk1. This hypoth-
esis is supported by our experiment with E1A oncoprotein, which binds and inhibits RB family members by 
disrupting E2F-RB1 interactions52, thus increasing Chk1 promoter activity, especially in MKN45 cells with higher 
levels of RB1. In addition, in response to E2F1 overexpression these cells are unable to increase Chk1’s mRNA.
Several studies have shown that both miR-15 and miR-497 families modulate multidrug resistance in GC 
cells by targeting BCl-253–56. Furthermore, this family of miRNA controls Chk1 protein levels. For instance, over-
expression of the miR-15a/b and miR-16 family affects the radiosensititivity of human breast cancer by regulat-
ing Chk1 and Wee1 proteins43. On the contrary, it has been shown that downregulation of the miR-15 family 
Figure 5. Nuclear Chk1 protein levels correlate with poor clinical outcome in human gastric cancer. 
(A) Immunohistochemical staining of Chk1 in representative carcinoma GC specimens: Nuclear positive 
and negative staining at 20 HPF (a,b respectively); nuclear positive and negative staining at 40HPF (a’,b’ 
respectively). The arrows point to strong Chk1 staining in the nucleus. (B) Kaplan-Meier curves of progression-
free survival (PFS) in patients with high or low expression of nuclear Chk1 in their gastric tumors. Survival 
curves were statistically different when analyzed by the Breslow. IBM SPSS Statistics 22 software.
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regulates CDDP sensitivity by increasing Chk1 levels44. Other studies have demonstrated that dowregulation of 
miR-424 contributes to cervical cancer progression via upregulation of its target gene Chk111. Along these lines, 
our results show a significant downregulation of miR-195 and miR-503 expression in MKN45 radioresistant 
cells. Accordingly, NSCLC (non small cell lung carcinoma) shows lower miR-195 expression in the tumor than 
in adjacent tissues, and this lower expression has been associated with poorer overall survival57. However, in 
addition to our preliminary results, more experiments are needed to specifically confirm the impact of this fam-
ily of microRNAs on Chk1’s expression and to define its influence on radioresistance. Nonetheless, the inverse 
correlation between microRNAs and Chk1 would be a promising parameter to consider in the clinical setting. In 
this regard, recent evidence confirms our findings in lung cancer57 which supports the universal character of our 
observations. However, other putative targets of those microRNA should be taken into account, and also their 
relationship with E2F1-RB58, in order to describe a possible feedback loop that could be regulating each member.
In summary, in this study we demonstrate that gastric tumors can be stratified into radiation resistant or 
sensitive, according to the status of Chk1. Chk1 protein levels could be modified by pRB-E2F1, p53 or miRNAs 
that seem to regulate its expression Thus, the miR-195/Chk1 axis may be used as a new biomarker tool to pre-
dict individual response to adjuvant radiotherapy. We previously described the possibility to sensitize advanced 
tumoral gastric cancer cells by adjuvant chemotherapy based on paclitaxel and cisplatin59, as an alternative to 
non-resecable tumors. The data presented here could mark a step forward allowing the design of improved ther-
apeutic interventions for GC patients.
Materials and Methods
Cell lines. AGS and MKN45 human gastric adenocarcinoma cell lines were cultured in F12-Kaings and RPMI 
mediums respectively (Gibco), and supplemented with FBS (10% for AGS and 20% for MKN45). Cultures were 
maintained at 37 °C, 5% CO2 and 95% humidity. AGS and MKN45 are wild type for TP5337,38.
Cloning. Genomic DNA was extracted from the colorectal cancer cell line HCT116 and the required sequence 
(− 1823 –284) was cloned into a pGL3-enhanced luciferase plasmid vector. See Supplementary M&M for details.
PCR. Total RNA was extracted using Tri-Reagent (Life technologies). Gene expression levels were assessed by 
Q-PCR, by using SYBR green-based chemistries for amplicon detection. For relative quantification (RQ) we used 
the delta-Ct method. Statistical analyses was performed for each gene by using a paired t-test to compare mean 
values, where p < 0.05 was considered significant.
Reagents and Plasmid Vectors. Cisplatin, 5-Fluorouracile, Actinomycin D and UCN-01 were pur-
chased from Sigma Aldrich. BLM was purchased from Calbiochem. pGL3 Basic and pGEMT easy (Promega), 
pSG5-HEY1, and pSG5 (Dr. B. Belandia), pCMV-E2F1 (Dra. A. Zubiaga), pcdna-p53DN (Dr. I Palmero), 
PCEFL-E1A, PEF1-p53 wt and pEF1 Dn (Dr. Sanchez-Prieto).
Luciferase activity assay. Constructs carrying the luciferase gene were cotransfected with 1 ng of Renilla 
(transfecting control, 1:100) using lipofectamine 2000 (Invitrogen) in 24 well plates following the Manufacter’s 
instructions. 24 hours after transfection, transcriptional activity was quantified using the Dual-Luciferase® 
Reporter (DLR™ ) Assay System (Promega) using a Promega luminometer.
Cell viability Clonogenic assay. Viability was determined using a MTS (Promega) staining method, as 
described60. To assess the effects of irradiation, cells were irradiated with different doses of Gy (0–8 Gy) using a 
137Cs source (mark 1, model 30, JL. Shepherd & Associates San Fernando CA; Dose rate to 100 mm diameter sam-
ples is ~370 R/minute). 15 days after treatment, colonies containing more than 50 individual cells were counted 
using a microscope and survival fractions were quantified as described61.
IC50 and Combination Index (CI). IC50 were calculated by using the GraphPad Prism program. We used 
nonlinear regression to fit the data to the log (inhibitor) vs response (variable slope) curve.
Effects of BLM and UCN-01 combination on growth inhibition were analyzed by the Combination Index (CI) 
equation developed by Chou-Talalay35,62 using the CalcuSyn program (Biosoft, Cambridge, UK). The general 
equation for the classic isobologram is given by: CI = (D)1/(Dx)1 + (D)2/(Dx)2 where CI < 1 indicates syner-
gism; CI = 1 indicates additive effect, and CI > 1 indicates antagonism; (Dx)1 and (Dx)2 in the denominators are 
the doses (or concentrations) of D1 (drug #1, for example, BLM) and D2 (drug #2, for example, UCN-01) alone 
that gives x% inhibition, whereas (D)1 and (D)2 in the numerators are the doses of D1 and D2 in combination 
that also inhibits x% The (Dx)1 and (Dx)2 can be readily calculated from the median-effect equation of Chou 
Dx = Dm[fa/(1-fa)]1/m where Dx is the median-effect dose, fa is the fraction affected, Dm is the median-effect 
dose signifying potency and m is the kinetic order signifying the shape of dose-effect curve.
Western blotting. Twenty μ g of protein per sample were loaded in SDS-PAGE in 10% (for E2F1,Chk1 
and p53) or 8% (for Rb or PARP-1) polyacrylamide gels, and then transferred onto nitrocellulose membranes. 
Antibody dilutions were as follows: Chk1- 1:500 (sc-377231), E2F1- 1:1000 (sc-193), Rb- 1:200 (sc-102), PARP-
1- 1:1000 (H-300: sc-25780), Cleaved Caspase-3 (Asp175) Antibody #9661 1:1000, p53 Antibody #9282 1:1000 
(Cell signaling) in 5% fat free milk 0’05% TTBS. HA Antibody- 1:2000 ( Boehringer mannheim), Flag antibody- 
1:2000 ( Sigma)
Cell cycle analysis. Cell cycle analysis was performed as previously described59. Supplementary M&M for 
details.
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Viral transduction of target cells. Viral particles for infection were generated according to manufacturing 
instructions using GIPZ Lentiviral shRNA for CHK1 (Thermo Scientific Open Biosystems). See Supplementary 
M&M for details.
miRNA analysis. RNA was purified from cultured cells using mirVana™ miRNA Isolation Kit (Ambion; 
Life Technologies). RT: TaqMan® MicroRNA Reverse Transcription Kit and TaqMan microRNA specific assays 
(Catalog #: 4427975 ID: 00104; ID: 000494: ID: 001973) were used to perform the RT and quantitative PCR 
(RT-qPCR) of triplicate samples. Real-time PCR was performed on an Applied Biosystems Step-one plus PCR 
(Life Technologies) following the manufacturer’s instructions. Total RNA input was normalized using RNU6B 
RNA as an endogenous control.
Gene expression profile analysis. The miRNA expression data in a large set of GC patient samples42 was 
downloaded from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and analyzed using 
custom R scripts for statistical programming http://www.r-project.org/“. Briefly, we compared probe values in 
each sample group (“normal”, “pretreatment”, “post-treatment”) using a Student’s t-test and the resulting p-values 
were adjusted for multiple testing by the Bonferroni method.
Patients and tumor samples. Patients (n = 23) were recruited from the Oncology Department at the 
Infanta Sofía´s Hospital between 2008 and 2015. We selected those patients diagnosed with GC, who underwent 
radical surgery and received adjuvant therapy according to the MacDonald´s treatment guidelines (5-FU and 
radiation). The specimens were collected during tumor resection. Tissue samples were histologically confirmed 
as tumoral or non-tumoral tissues, and were stored at − 80 °C until analysis. This study was approved by the 
Clinical Research Ethics Committee “IMDEA alimentacion” (code IMD: PI-010). All procedures were carried out 
in accordance with the approved guidelines and after informed consent was obtained from all subjects included 
in the study.
Immunohistochemical analysis. Immunohistochemistry was performed in 3-μ m sections of 
paraffin-embedded tissues. Samples were deparaffinized and rehydrated in water, after which antigen retrieval was 
carried out by incubation in EDTA solution. Endogenous peroxidase and non-specific antibody reactivity were 
blocked with peroxidase blocking reagent (Dako). The sections were then incubated with the Rabbit Monoclonal 
Antibody against Chk1 (TA300658. Origene Technologies). Detection was carried out by using Envision Plus 
Detection System (Dako). Negative controls were performed by replacing the primary antibody with goat serum. 
The slides were finally mounted with DPX mountant for microscopy (VWR Int). Immunohistochemical analysis 
was performed by the Pathology department’s staff at the same Hospital and the interpretation by a blinded expert 
pathologist. Chk1 nuclear staining was assessed as a percentage of surface showing positive signal, relative to the 
percentage of stained cells in the sample per surface area. A semi-quantitative score was assigned, as follows: 0: 
≤ 10%; 1: 10–25%; 2: 25–50%; 3: ≥ 50%. Positive staining was therefore considered 1, 2 or 3.
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